- Conditions
- Adverse Effects in the Therapeutic Use of Plasma Substitutes
- Interventions
- Octaplas™
- Biological
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- 2 Years to 20 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • New Orleans, Louisiana + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–56
of 56
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Atypical Hemolytic Uremic Syndrome
- Interventions
- Eculizumab
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Fort Wayne, Indiana • New York, New York + 2 more
- Conditions
- Multiple Myeloma, Light Chain Nephropathy, Acute Kidney Injury
- Interventions
- Plasma exchange, Daratumumab
- Procedure · Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 549 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Relapsing Forms of Multiple Sclerosis
- Interventions
- Plasma exchange, natalizumab treatment
- Procedure · Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio • Milwaukee, Wisconsin
- Conditions
- Alzheimer Disease
- Interventions
- Not listed
- Lead sponsor
- MaxWell Clinic, PLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Brentwood, Tennessee
- Conditions
- Lung Transplant Rejection
- Interventions
- Carfilzomib
- Drug
- Lead sponsor
- John F. McDyer, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Cytokine Release Syndrome, COVID19
- Interventions
- Therapeutic Plasma Exchange, Ruxolitinib
- Procedure · Drug
- Lead sponsor
- Prisma Health-Upstate
- Other
- Eligibility
- 12 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Greenville, South Carolina
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Standard Steroid Treatment, The Standard Steroid Treatment, Plasma Exchange and rituximab
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 90 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 5
- States / cities
- Danville, Pennsylvania • Philladelphia, Pennsylvania • Pittsburgh, Pennsylvania + 2 more